G
ene therapy for the treatment of inherited disorders such as adrenoleukodystrophy (Cartier et al. 2009 ), adenosine deaminase-related severe combined immunodeficiency (Gaspar et al. 2011) , and the childhood blindness Leber congenital amaurosis (LCA) (Bainbridge et al. 2008; Hauswirth et al. 2008; Maguire et al. 2009 ) have recently shown great promise. Inherent to the success of these clinical trials was the availability of animal models to test therapeutic strategies. For instance, gene replacement with an adeno-associated virus (AAV) vector to treat RPE65-associated LCA (LCA2) was largely successful in both the Rpe65 2/2 mouse and the large Briard dog model of the disease . In comparison to contralateral sham-injected eyes, electroretinogram (ERG) responses and visual acuity increased significantly in Rpe65 2/2 mouse eyes treated subretinally with an AAV-RPE65 vector. Similarly, subretinal AAV-RPE65 delivery resulted in significant reversal of nystagmus and visual deficits in RPE65 mutant dogs (Acland et al. 2001 (Acland et al. , 2005 Narfström et al. 2003) . Notably, ERG a-waves, indicative of photoreceptor responses, also increased dramatically (by 26% -60%) and persisted for the duration of the study following injection of the therapeutic gene transfer vector. The kinetics of the a-waves were not significantly different between treated and phenotypically normal animals . These promising findings paved the way for the development of AAV-mediated RPE65 gene replacement therapy for patients with LCA2.
ANIMAL MODELS AND THERAPEUTIC GENE TRANSFER
Although animal models are invaluable for investigation of disease pathophysiology and evaluation of gene transfer strategies, not all models faithfully recapitulate the human phenotype. This is especially true when developing therapeutic strategies for the treatment of inherited macular degenerations. For example, the study of gene transfer for the treatment of age-related macular degeneration (AMD), Stargardt disease, and Best disease are hampered by the fact that the rod-dominant mouse retina lacks a macula, the central zone of the primate retina that has evolved to subserve very fine visual acuity. Similarly, many disease models have a drastically different age of onset and disease progression than is observed in the human condition. For instance, dominant Pro23His rhodopsinassociated retinitis pigmentosa typically causes relatively late-onset disease in humans, with significant vision remaining until late in life. The pig model of Pro23His rhodopsin-associated retinitis pigmentosa has a retinal disease that is significantly more aggressive than that seen in humans; as early as 3 mo of age, these animals have extensive photoreceptor cell loss ( Fig.  1) (Ross et al. 2012) . Similarly, in the rd16 CEP290 mouse model of LCA, mice are born with a full complement of photoreceptor cells, but the very aggressive disease results in almost complete loss of photoreceptor cells by 3 wk of age (Chang et al. 2006) . The fact that a large proportion of the photoreceptor cells are lost before the eyes open makes gene transfer approaches for the treatment of this disease very difficult.
Advances in pluripotent stem cell technologies provide an exciting avenue for the treatment of retinal degenerative disease. For instance, human embryonic stem cell (ESC)-derived photoreceptor precursor cells transplanted into a mouse model of retinal degeneration have been shown to migrate into and integrate within the degenerative retina, express rod and cone photoreceptor markers and restore electroretinal activity (Lamba et al. 2009 ). However, ESCderived photoreceptor transplants are by definition allogeneic and would likely require life-long immune modulation if used clinically (PreynatSeauve et al. 2009; West et al. 2010) . Like ESCs, patient-specific induced pluripotent stem cells (iPSCs) possess the ability to differentiate into photoreceptor precursors which can integrate into a diseased retina and give rise to new functional photoreceptor cells (Lamba et al. 2010 ; Figure 1 . The transgenic pig carrying a human Pro23His rhodopsin transgene displays drastically accelerated retinal degeneration. A-B: Histological analysis of both wild-type (A) and Pro23His (B) pig retinal tissue at 6 mo of age. C-D: Cytochemical analysis of both wild-type (C) and Pro23His (D) pig retinal tissue at 6 mo of age, using wheat germ agglutinin (WGA, red) and DAPI (blue). Homma et al. 2013; Tucker et al. 2013b ). However, unlike ESCs, iPSCs can be autologous and thus have a greatly reduced risk of being rejected by the host immune system.
Patient-derived iPSCs can be generated in 4-6 wk via forced factor expression in a variety of cell types. Takahashi and Yamanaka first showed this concept through retroviral-mediated expression of the transcription factors OCT4, SOX2, KLF4, and cMYC in mouse embryonic fibroblasts (Takahashi and Yamanaka 2006) and human primary dermal fibroblasts (Takahashi et al. 2007 ). In addition to the "Yamanaka factors," Yu and colleagues in the Thomson laboratory established that the factors OCT4, SOX2, LIN28, and NANOG were capable of generating induced pluripotent stem cells from mesenchymal cells (Yu et al. 2007 ). Many cell types have since been reprogrammed using forced factor expression including dermal keratinocytes (Carey et al. 2009 ), neural progenitor cells (Kim et al. 2011) , hepatocytes (Liu et al. 2010) , and peripheral blood cells (Loh et al. 2009 ). Since Yamanaka's seminal report, several groups showed reprogramming using many delivery methods-both integrating and nonintegrating. Integrating lentiviral vectors are widely used for delivery of reprogramming transgenes (Brambrink et al. 2008; Maherali et al. 2008) . However, to avoid the insertional mutagenic risk associated with integrating vector systems, investigators use adenovirus (Stadtfeld et al. 2008 ), Sendai virus (Jin et al. 2012 Tucker et al. 2013a) , and transient plasmid delivery (González et al. 2009; Si-Tayeb et al. 2010) . For a more detailed description of these and other delivery methods please refer to reviews (Malik and Rao 2013; Hu 2014) .
Beyond being an attractive cell source for retinal transplantation, the patient-specific nature of the iPSC makes this technology very attractive for disease modeling and investigation of disease pathophysiology. That is, the molecular causes of clinical variations in disease can be studied by comparing cells derived from mildly and severely affected individuals. For example, fibroblast cultures from CEP290-associated LCA patients with different genotypes show cellular phenotypes of varying degrees of severity (Burnight et al. 2014) . iPSC-derived photoreceptors from each of these patients can be used to study the molecular causes of the phenotypic variation observed. The efficacy of novel therapies can also be tested on cells of the actual patients who might be treated.
INDUCED PLURIPOTENT STEM CELLS AS PATIENT-SPECIFIC MODELS TO TEST EXOGENOUS GENE DELIVERY
There are many vector systems from which to choose when developing a strategy for the treatment of an inherited retinal degenerative disease. For in vivo gene transfer, there are several obstacles to the effective delivery and expression of therapeutic transgenes. In many cases, gene delivery methods must overcome host immunity (Reichel et al. 1998; Ikeda et al. 2002; Li et al. 2008) . Moreover, certain cell and tissue types are difficult to transduce in vivo, which is likely because of a combination of incompatible vector tropism and limited diffusion away from the injection site. Gene delivery to cells ex vivo (i.e., "in a dish"), circumvents many of these limitations and shifts the scientific focus from the delivery vehicle to the genetic cargo. This is of particular value when one wishes to choose among several possible promoters, evaluate gene function, and determine the optimal level of transgene expression without killing dozens, if not hundreds, of animals in the process.
One of the major considerations when determining which vector system to use is gene size. Small, nonstructural enzymes (i.e., MAK, RPE65, etc.) are often well-suited for expression via the AAV vector system Conlon et al. 2013; Molday et al. 2013; Dai et al. 2014) . Indeed, the recent success of clinical trials involving patients with LCA2 highlights the utility of the AAV vector for in vivo gene transfer to the retina (Bainbridge et al. 2008; Hauswirth et al. 2008; Maguire et al. 2008) . However, the natural serotypes of AAV do not transduce human pluripotent stem cells very efficiently. The commonly used AAV2 serotype transduces human stem cells only marginally (10% at a multiplicity of infection of 10,000 [Asuri et al. 2012] ). Asuri and colleagues (2012) addressed this limitation via directed evolution of the capsid, which yielded threefold higher transduction efficiency when transduced at an equal multiplicity of infection. Another consideration when using AAV vectors in gene transfer studies is the packaging limit. Large genes such as CEP290 ( 8 kb coding sequence) or ABCA4 ( 6.5 kb coding sequence) require vectors that can accommodate more than the 4.5 kb packaging limit of AAV (Wu et al. 2010) . To this end, the lentivirus is an attractive choice. The packaging limit of lentivirus is 8210 kb (Balaggan and Ali 2012) and can thus accommodate larger transgene expression cassettes. Moreover, lentiviruses can be pseudotyped with a variety of pantropic envelope glycoproteins (Calame et al. 2011 )-the most common of which is the G glycoprotein of the vesicular stomatitis virus (VSVG)-and can transduce pluripotent stem cells well (Endo et al. 2007; Tucker et al. 2011) .
We have employed lentiviral-mediated gene transfer to transduce pluripotent stem cell-derived photoreceptor precursor cultures from patients with LCA and retinitis pigmentosa. For example, the most common cause of retinitis pigmentosa in the Jewish population is a splicealtering insertion of an Alu element in the male germ cell-associated kinase (MAK) gene. Cilia formation assays showed that patient's cells generated elongated cilia when compared with phenotypically normal cells (Tucker et al. 2011 ). On transduction with VSVG-pseudotyped lentiviral vectors expressing MAK, cells formed significantly shortercilia compared with untransduced cultures. Thus, we achieved functional gene correction in patient-specific, stem cell-derived photoreceptor precursors. For treatment of patients with LCA, we successfully packaged cDNA encoding the large structural gene CEP290 into lentiviral vectors with the heterologous cytomegalovirus (CMV) promoter driving transgene expression (Burnight et al. 2014) .
Another important consideration in developing gene transfer strategies to treat inherited disorders in vitro is the timing of the genetic correction. Is it more effective to perform gene transfer to the somatic cells (i.e., fibroblasts or keratinocytes) before reprogramming them into iPSC cultures, or to differentiate the cultures first and then transduce them? Long-term gene expression in immature cell types transduced with g-retroviral and lentiviral vectors can be silenced because of epigenetic mechanisms such as DNA methylation or histone modification of the heterologous promoter (Ellis 2005; Herbst et al. 2012) . For example, transgene silencing was observed in iPSCs derived from a murine model of tyrosinemia type 1 (FAH -/ -) after transduction with a lentivirus expressing FAH (Wu et al. 2011) . Only 20% of cells expressed the transgene. Nonetheless, a small percentage of these genetically corrected iPSCs showed full pluripotent potential, and viable mice were generated via tetracomplementation (Wu et al. 2011) .
Because phenotypic correction is not as efficient when transducing iPSCs (because of transgene silencing), it may be more advantageous to correct somatic cells before reprogramming. For example, Raya and colleagues transduced fibroblasts from Fanconi anemia patients with lentiviral vectors expressing FANCA or FANCD2. These cells, on reprogramming, expressed the pluripotency markers OCT4, SOX2, NANOG, SSEA3, SSEA4, and TRA1-60, and were indistinguishable from human embryonic stem cells and iPSCs from healthy individuals. Moreover, the genetically corrected iPSCs differentiated into phenotypically normal myeloid and erythroid progenitors (Raya et al. 2009 ).
Introducing therapeutic transgenes after differentiation is also a viable option in some cases. We recently showed successful lentiviral gene transfer to differentiated photoreceptor precursor cultures from patients with CEP290-associated LCA. Transduced photoreceptor precursor cells (identified by expression of retinal markers OTX2, OPSN1SW, and ROM1) expressed CEP290 transcript and full-length protein after 90 d of differentiation (Burnight et al. 2014 ). Furthermore, a cilia formation defect that was identified in serum-starved fibroblasts isolated from a CEP290 patient carrying two hypomorphic alleles was rescued following transduction with the CEP290-expressing lentiviral vector described above (Burnight et al. 2014) .
Effective gene therapy strategies must result in therapeutic transgene expression in the ap-E.R. Burnight et al. propriate cell type and at the appropriate level. Transgene expression is commonly driven by strong, ubiquitously expressing promoter elements, such as CMV. However, overexpression of large structural proteins such as CEP290 or members of the BBSome, a complex of proteins associated with Bardet-Biedl syndrome, may lead to cytotoxicity and cell death (Seo et al. 2013; Burnight et al. 2014) . For an inherited retinal disease, it is important to direct the appropriate level of expression in the cell type specific to the pathophysiology of the disease. Thus, developing a "molecular toolbox" of gene transfer reagents is of great interest. This array of reagents would include promoters specific to heterologous cell or tissue types with varying degrees of expressivity and a series of viral vectors with a range of carrying capacities (Fig. 2) . Indeed, work from our laboratory and others indicates promoter elements from retina-specific genes such as GRK1, IRBP, RHO, PDE, NRL, and RCVRN achieve photoreceptor-specific expression both in vitro and in vivo (Nicoud et al. 2007 ). However, it has yet to be shown whether issues relating to the level of transgene expression and cellular toxicity will remain. For some genes, precise stoichiometry may require identification and use of the endogenous promoter of the therapeutic gene. Conversely, a series of cell type-specific promoters, such as those indicated above, with tunable expression elements may be useful. The ability to efficiently generate and test these reagents will almost certainly benefit from the ability to create disease-specific cell types from affected individuals.
GENOME EDITING
As indicated above, successful genetic correction in iPSCs was achieved through gene augmentation using exogenous vector systems. Therapeutic transgene expression in the retina persists for long periods of time, reducing the need for vector readministration (Bemelmans et al. 2008; Ikeda et al. 2009; Koirala et al. 2013; Testa et al. 2013 ). However, integrating vectors such as those derived from g retrovirus carry the inherent risk of inducing insertional As was shown by Hacein-Bey-Abina et al., some patients who received ex vivo gene augmentation via a g-retroviral vector developed a T celllike leukemia as a result of vector insertion and proto-oncogene activation in treated cells. This adverse event highlights the mutagenic risk involved with employing integrating vectors. Furthermore, given the fact that precise regulation of gene expression may be required, the ability to genetically modify defective genes in vitro provides an attractive strategy for both the creation and the repair of disease-causing mutations. Development of patient-specific autologous cells for transplantation would greatly benefit from such a strategy.
The use of genome editing tools such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the recently reported clustered regularly interspersed short tandem repeat (CRISPR)/Cas system is increasing. By editing the mutation directly through double-strand break induction by a genome editing reagent and subsequent homology-directed repair, one can take advantage of the endogenous expression control elements (i.e., promoters, enhancers, and repressors). This approach addresses some of the more serious limitations of gene replacement such as inappropriate spatial expression or incorrect levels of expression from heterologous promoters as well as the possibility of activation or inactivation of deleterious genes from vector integration.
In nature, transcription activator-like (TAL) effector proteins are transcription factors used by the plant pathogen Xanthamonas to evade host immune mechanisms (Gu et al. 2005; Kay et al. 2007; Sugio et al. 2007 ). The DNA targeting domain in the TAL effector protein consists of tandem repeats of 34 amino acids, at the center of which is a highly variable pair of amino acids that confer nucleotide specificity (Schornack et al. 2006) . The DNA recognition "code" was recently deciphered (Boch et al. 2009 ; Moscou and Bogdanove 2009), allowing TAL effectors to be engineered to recognize specific sites in the genome. Complexing the engineered TAL effectors with the nuclease domain of the type-II restriction endonuclease FokI can induce double-strand breaks at specific sites at or near mutations in patient-specific iPSCs. When codelivered with a donor cassette containing a corrected sequence, homology-directed repair can result in genetic correction of these cells.
Recently Hockemeyer and colleagues (2011) targeted three endogenous loci, PPP1RP12C, OCT4, and PITX3, with engineered TALENs. TALEN expression constructs and donor cassettes were electroporated into both human ESCs and iPSCs. The researchers reported targeting efficiencies of 50% -100% depending on the locus. To assess binding specificity of the PPP1RP12C TALEN pair, Hockmeyer et al. interrogated the 19 top-ranked, maximal-likelihood potential off-target sites, as determined using systematic evolution of ligands by exponential enrichment (SELEX)-derived base-frequency matrices (Perez et al. 2008) . NextGen Illumina sequencing revealed insertions or deletions at off-target sites at a very low rate (0.01%), indicating the TALENs were quite specific. Southern analysis at all three sites indicated modification at the intended site only, confirming these results (Hockemeyer et al. 2011 ). This valuable series of experiments provides support for the feasibility of successful genome modification in pluripotent stem cells, and suggests a powerful method for employing genetic repair in patient-specific, iPSC-derived photoreceptor precursor cells for treatment of inherited retinal degenerations. That said, before clinical use, it will be important to assess offtargeting in cells treated with genome editing reagents to prevent unwanted outcomes. Double-strand breaks are induced via heterodimerization of the FokI nuclease domains from two engineered TALENs targeted to half-recognition sequences at the intended locus. An unintended outcome of TALEN expression is the formation of homodimers, from which off-target cleavage can result. Thus, reengineering the FokI catalytic domain such that TALEN pairs form obligate heterodimers reduces the frequency of off-target cleavage (Doyon et al. 2011; Hockemeyer et al. 2011; Ramalingam et al. 2011) .
Recently, the CRISPR/Cas system has been introduced (Cong et al. 2013; Jinek et al. 2013; Mali et al. 2013 ) and offers several advantages for genome editing in iPSCs. First, CRISPR reagents are easier to design and work more predictably because their DNA targeting is based on RNA hybridization instead of the zinc-finger protein binding of TALENs. The guide RNA of the CRISPR system consists of an NGG sequence ( protospacer adjacent motif, or PAM) downstream from the 20-nucleotide target (Cho et al. 2013; Cong et al. 2013; Mali et al. 2013) . One can generate a CRISPR targeting reagent by simply synthesizing these guide sequences as complementary oligonucleotides and ligating them into a bicistronic vector that also contains a Cas9 nuclease optimized for expression in human cells (Cong et al. 2013; Ran et al. 2013b) .
Recently, Mali and colleagues (2013) showed successful genome editing in human iPSCs using the CRISPR/Cas system. These researchers developed humanized CRISPR/Cas reagents targeting the endogenous AAVS1 locus. They showed homology-directed repair using a double-stranded DNA donor cassette in 2% -4% of fibroblast-derived iPSCs generated from participants in the Personal Genome Project (PGP).
As with TALEN and ZFN technology, the possibility of toxicity from off-target doublestranded breaks must also be addressed when employing the CRISPR/Cas system (Fu et al. 2013) . Targeting via CRISPR/Cas can tolerate mispairing of the 20-nucleotide guide RNA (Cong et al. 2013; Jinek et al. 2013) , which creates the potential for double-stranded breaks at unintended genomic loci. To address this issue, Cong et al. (2013) mutated a single amino acid in the catalytic domain of the Cas9 nuclease, thereby limiting the enzyme's activity to single-strand "nicks." These "nicks" can be repaired by the endogenous base excision repair pathway (Lindahl 1993) . By using guide RNAs with a mutant Cas9 "nickase," targeted to sequences on opposite strands, one can increase editing specificity and significantly reduce offtarget toxicity. For example, Ran and colleagues (2013a) recently showed efficient modification (.40%) at three loci in human cells using paired nickases targeting sequences separated by four to 20 bases on opposite strands of genomic DNA. Moreover, using deep sequencing analysis of off targets, these investigators showed a 200-to 1500-fold increase in specificity when compared with wild-type Cas9. Ran and colleagues extended these studies in vivo by coinjecting guide RNAs targeting the Mecp2 locus and either mutant or wild-type Cas9 mRNA into single-cell mouse zygotes. These experiments yielded .80% modification at the intended locus. A previous study also supported in vivo genome editing with the CRISPR/Cas system. Wang et al. injected wild-type Cas9 and guide RNAs targeting the Tet1 and Tet2 loci as well as oligo repair templates into zygotes and generated mice with modification of both genes at a rate of 80% ). This elegant set of experiments show the utility of employing nickases to increase specificity and safety of the valuable genome editing CRISPR/Cas technology for both in vitro and in vivo studies (Ran et al. 2013a; Wang et al. 2013) . To treat patients who have molecularly confirmed retinal degenerative disorders, CRISPR/Cas reagents can be delivered to patient-derived iPSCs to correct disease-causing mutations before differentiating into photoreceptor precursor cells for transplantation. For in vivo therapeutic use, the addition of inducible promoters to allow transient expression of the guide RNAs may be desirable to further reduce off-target effects. Should CRISPR/Cas technology prove safe and effective for in vivo studies, many of the challenges associated with delivering large transgenes and regulating their level of expression may be overcome.
CONCLUDING REMARKS
In the not-too-distant past, the prognosis for patients affected with an inherited retinal disorder was grim. Patients were often told that there was nothing that could be performed and that their fate was irreversible blindness. Fortunately, with developments in stem cell and gene transfer technologies there is now realistic hope for treating many of these individuals. The ability to accurately identify a patient's disease-causing mutations is a prerequisite to the development of both gene-based and autologous cell-based therapies. As depicted in Figure 3 , one can envision a strategy in which high-quality genetic testing, coupled with in vitro patient-specific, stem cell-based model systems, will allow for the rapid development of gene-and cell-based treatments. This process would begin by collecting blood and skin samples from the affected patient. DNA isolated from blood would be subjected to genetic screening to identify potential disease-causing mutations, and skinderived fibroblasts or keratinocytes would be harvested for generation of iPSCs. To confirm pathogenic mutations and elucidate pathophysiologic mechanisms, iPSC-derived photoreceptor precursor cells, generated via directed differentiation, could be subjected to a variety of pathway-specific analyses. Disease-specific phenotypes identified in these studies would be used to test and confirm the efficacy of gene transfer and genome editing approaches. Gene transfer vectors shown to be effective at correcting the disease phenotype would then be used to treat patients' remaining photoreceptor cells. For patients with extensive photoreceptor cell loss, an autologous cell replacement strategy using patient-specific photoreceptor precursor cells genetically corrected via CRISPR-or TALEN-based genome editing would also be employed. This approach could be used to treat inherited retinal disorders, regardless of the clinical stage and prevalence of the disease, and regardless of the size of the causative gene. 
